Efficacy, Safety, and Tolerability of Oral Eletriptan for Treatment of Acute Migraine

• Status: Completed
• Trial end date: 1997-12-01
• Target enrollment: 0
• Participant gender: All

Summary

To confirm the efficacy of three dose levels of oral eletriptan relative to placebo in relieving symptoms of acute migraine and to further explore the dose response relationship of eletriptan.

• Phase: Phase 3
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Pfizer; Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
• Treatments: Eletriptan

Criteria

Inclusion Criteria:

• History of at least one typical attack of migraine with or without aura every 6 weeks, as defined by the International Headache Society (IHS) criteria.

• Capable of taking study medication as outpatients and recording its effects.

Exclusion Criteria:

• Pregnant or breast-feeding women

• Migraine subjects who also suffered from concomitant frequent (non-migraine) headache, defined as more than six headaches per month on average

• Migraine attacks that were thought to be atypical and had consistently failed to respond to medical therapy.